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Endothelial function and adrenergic reactivity 
in human type-II diabetic resistance arteries 
Mari lyn J. Cipolla, MS, Christ ian T. Harker ,  PhD,  and John  M. Porter ,  MD,  
Portland, Ore. 
Purpose: This study was performed to examine the role of  the vascular endothelium in 
modulating arterial reactivity to adrenergic vasoconstriction in subcutaneous arteries from 
patients with type I I  diabetes. 
Methods: Small subcutaneous arteries (inner diameter = 90 to 180 ~tm) from control 
subjects (n = 22) and patients with diabetes (n = 18) were dissected from skin biopsies 
obtained at surgery and mounted on a specialized arteriograph t at allowed for continuous 
measurement ofhtmen diameter under controlled pressure. The sensitivity to norepineph- 
fine was compared in arteries that were either intact, denuded of endothelium, or intact 
and exposed to Nc0-nitro-L-arginine (L-NNA), an inhibitor of  nitric oxide synthesis. 
Stimulated release of  nitric oxide by acetylcholine and smooth muscle cell responses to 
sodium nitroprusside were also evaluated in diabetic and control arteries. 
Results: Sensitivity to norepinephrine was augmented in diabetic arteries and the amount 
of  agonist necessary to contract the vessels 50% of maximum (EC5o) decreased from 0.35 
+ 0.05 gmol /L  in the control arteries to 0.16 + 0.06 gmol /L  in the diabetic arteries 
(p < 0.05). Both endothelial removal and blockade of  nitric oxide synthesis increased 
sensitivity to norepinephrine in control arteries (ECso a~nuaea = 0.14 _+ 0.03 btmol/L and 
E C50 I.-~NA = 0.14 + 0.04 gmol /L ;  p < 0.01 ) but failed to augment sensitivity in diabetic 
arteries (ECso denuded = 0.17 + 0.05 ~tmol/L and ECs0 L~NA = 0.15 + 0.04 gmol /L ;  
p > 0.05). Stimulated release of  nitric oxide by acetylcholine was increased in the diabetic 
arteries: ECso cont~o~ = 0.04 _+ 0.01 gmol /L  versus ECso d~abe~i~ = 0.009 + 0.001 ~tmol/L 
(p < 0.05). Sensitivity of  vascular smooth muscle to sodium nitroprusside was similar in 
both nondiabetic and diabetic arteries. 
Conclusions: The endothelium itigates adrenergic reactivity in control arteries, which is 
lacking in diabetic arteries and results in enhanced reactivity to norepinephrine; increased 
sensitivity of  diabetic arteries to acetylcholine, however, indicates a possible alteration at 
the receptor level. (J Vasc Surg 1996;23:940-9.) 
Vascular damage associatcd with diabetes mellitus 
underlies many of  the major complications o f  this 
disease, including atherosclerosis, hypertension, ret- 
inopathy, and chronic ulceration. 1'2 Although the 
cause of  diabetic vascular disease is not understood, 
enhanced reactivity of  the resistance vcssels to circu- 
lating hormones and neurotransmitters may contrib- 
ute by altering peripheral vascular resistance and 
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blood flow regulation. 3'4 Several studies have shown 
increased sensitivity to adrenergic agonists in isolated 
vascular preparations from animals with experimen- 
tally induced diabetes, -7 In vivo studies in patients 
with diabetes have also demonstrated increased arte- 
rial responsiveness to circulating catecholamines, in- 
cluding c~-adrenergic agonists, ,vithout a correspond- 
ing increase in serum levels, suggesting altered vascu- 
lar function, s 
The vascular endothelium synthesizes and secretes 
both vasoconstricting and vasorelaxing factors and is 
an important mediator o f  vascular tone. 9 Endothe- 
lium-derived nitric oxide (NO) is a vasodilator pro- 
duced by the vascular endothelium under basal con- 
ditions, the release of  which is stimulated by a variety 
o f  receptor-mediated agonists, as well as mechanical 
stimuli, including shear stress. 9'1° Blockade of  NO 
synthesis with inhibitory L-arginine analogs leads to 
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significant peripheral vasoconstriction a d increased 
blood pressure, 11,12 indicating that NO acts as an 
endogenous vasodilator counterbalancing both neu- 
rogenic and myogenic vasoconstriction. 
Isolated artery preparations from diabetic ani- 
mals and forearm perfusion studies of patients with 
type I diabetes have demonstrated abnormal endot- 
helial function, including impaired NO-mediated 
vasodilation. 13-18 It is unknown whether diminished 
vasorelaxant synthesis or release in type II diabetic 
subcutaneous arteries from human beings contrib- 
utes to enhanced adrenergic vasoreactivity. En- 
hanced adrenergic reactivity in subcutaneous arteries 
may contribute to increased peripheral vascular e- 
sistance, altered blood flow regulation, and compli- 
cations of the subcutaneous vasculature such as di- 
minished wound healing, chronic ulceration, and 
amputation. This study was performed to determine 
the role of the endothelium in modulating arterial 
reactivity to norepinephrine in isolated resistance 
arteries from control subjects without diabetes and 
patients with type II diabetes. Resistance-sized ar- 
teries (inner diameter < 200 btm/L) were studied 
because they are believed to have the most potential 
influence over blood flow regulation and contribu- 
tion to peripheral vascular esistance. 
MATERIAL AND METHODS 
Subjects 
All arteries for experimentation were taken from 
lower extremity skin and subcutaneous fat biopsies 
obtained from patients undergoing lower extremity 
vascular surgery. Patients were age matched, had 
similar body weights, and were classified as either a 
control subject without diabetes or a patient with 
type II diabetes as indicated in the patient's medical 
record. Because all arteries obtained were from pa- 
tients undergoing vascular surgery, the control popu- 
lation for this study was not healthy. All had symp- 
tomatic arterial occlusive disease. Several had modest 
hypercholesterolemia (six of 21) and many had other 
vascular complications including angina, kidney dis- 
ease, ulcers, congestive heart failure, and Raynaud's 
disease. Most control subjects without diabetes were 
receiving medications including warfarin (Couma- 
din; n = 5), aspirin (n = 7), calcium channel blockers 
(n = 9), cholesterol-lowering medications (n = 6), 
and diuretics (n = 4). Mthough a healthy control 
population may be desirable in some cases, we com- 
pared arterial responses from patients with diabetes 
with those from patients without diabetes with simi- 
lar vascular disease. We believe this approach is ap- 
propriate because any significant differences found 
will then be more attributable to diabetic compli- 
cations. 
The diabetic population had vascular disease simi- 
lar to the nondiabetic control group and was typical 
for patients with chronic type II diabetes, including 
peripheral vascular disease (n = 3), chronic ulcers 
(n -- 3), kidney disease (n = 4), coronary artery dis- 
ease (n = 2), and hypercholesterolemia (n -- 5). Most 
patients were receiving lucose-lowering medication 
other than insulin (sulfonylurea drugs), although 
three were taking insulin. Other medications were 
similar to the nondiabetic onn'ol population and 
included aspirin (n= 1), calcium channel blockers 
(n = 2), digoxin (n = 1), and diuretics (n = 1). 
Preparation of arterial segments and denudation 
This study was approved by the Oregon Health 
Sciences University Committee for Human Research, 
and informed consent was obtained from each pa- 
tient. At the time of surgery asmall piece (3.0 x 2.0 x 
1.0 crn) of skin and fat was removed from the edge of 
surgical incisions, placed in cold (4 ° C), oxygenated 
physiologic saline solution (Ringer's PSS) and imme- 
diately brought o the laboratory. For the salve of con- 
sistency, biopsies were taken from the groin area only. 
Small subcutaneous arteries (inner diameter =90 
to 180 bun~L) from control subjects without diabetes 
(n = 22) and patients with diabetes (n = 1.8) were 
carefully dissected from subcutaneous fat. The whole 
specimen was viewcd under a dissecting microscope at 
low power, and the fat was teased apart until a 
segment of vessel(s) was exposed. Because of the small 
size of these vessels, differentiation between veins and 
arteries was difficult. Arteries were identified by com- 
parison to adjacent parallel veins, which were larger, 
with visibly thinner walls. Arteries so verified were 
carefully dissected and cleared of extraneous fat and 
connectivc tissue and transferred either directly into 
the arteriograph chambers or to dissecting dishes for 
denudation. 
Endothelial denudation was accomplished by use 
of a technique previously published) 9 Briefly, the 
vessel to be denuded was transferred to a special 
dissecting dish containing several human hairs of 
varying diameters (50 to 100 ~tm/L), approximately 
1.0 cm in length, with one end attached by silicon 
epoxy to the base of the dish for stability. The artery 
was carefully slipped onto the free end of an appro- 
priately sized hair and pulled over the hair two to three 
times, thus removing the endothelial cells without 
damaging the surrounding smooth muscle. The ar- 
tery was then transferred into one of the arteriograph 
chambers. 
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Pressurized arteriograph system and 
measurement of  lumen diameter 
All experiments were conducted by use of a 
pressurized arteriograph system previously de- 
scribed, g° The arteriograph (Living Systems Inc., 
Burlington, Vt.) consisted of two 20 ml chambers 
with inlet and outlet ports to allow for superfusion of 
the arteries with PSS and for application of drugs. The 
superfusate (PSS) was continually recirculated from a 
50 ml reservoir and pumped via a peristaltic pump 
through a heat exchanger to warm the PSS to 37 ° C 
before entering the arteriograph chamber. The PSS 
was aerated in the reservoir with a mixture of 10% 02, 
5% CO2, and 85% N 2 to maintain a constant pH of 
7.4. 
Each of two arteriograph chambers contained a
set of proximal and distal glass microcannula (tip = 50 
btm/L) attached to maneuverable bulkheads to which 
an artery was mounted, secured with single strands of 
nylon suture (diameter =20 btm/L), and perfused 
with oxygenated PSS. The proximal cannula was 
attached to an in-line pressure transducer and servo- 
mechanism that continually measured and adjusted 
transmural pressure (TMP). The servomechanism 
system consisted of a small peristaltic pump and 
controller, which allowed the TMP to be either 
maintained at a set pressure (static) or increased at a 
variable rate. Each distal cannula was connected to a 
stopcock, which was turned off during the experi- 
ment, so that there was no flow through the vessel. 
After mounting one artery in each of the arteriograph 
chambers, the arteries were pressurized to 20 mm Hg 
by opening the proximal stopcock. 
Once both arteries were cannulated and pressur- 
ized, the arteriograph was transferred to an inverted 
microscope with an attached video camera nd mono- 
chrome monitor. Each cannulated artery was sus- 
pended on bulkheads just above an optical window in 
the bottom of the chamber to allow for viewing of the 
artery and electronic measurement of lumen diam- 
eter. The transilluminated image of the artery on the 
video monitor (only one artery can be viewed at a 
time) was used to electronically determine the dimen- 
sions of the artery by use of a technique first devised 
by Wiederhielm. 21A video signal was input into the 
video dimension analyzer in which the optical con- 
trast of the vessel wall was used to initiate and 
terminate a voltage ramp, the amplitude of which was 
proportionate o inner diameter. 22 The output (ana- 
log voltages) from the video dimension analyzer and 
the pressure controller was connected to an IBM- 
compatible 386 computer through a serial data ac- 
quisition system (Dataq Inc., Alcron, Ohio), permit- 
ling visualization of dynamic responses (diameter and 
TMP) similar to a chart recorder. 
Drugs and solutions 
The superfusate and perfusate for all experiments 
consisted of a phosphate-based bicarbonate buffer 
(Ringer's PSS), the ionic composition of which was 
(in millimoles per liter): NaCI 119.0, NaCHO~ 24.0, 
KC14.7, I(.H2PO 4 1.18, MgSO 4 " 7H20 1.17, CaCI 2 
1.6, ethylenediamine tetraacetic acid 0.026, and glu- 
cose 11.0. PSS was made each week and stored 
without glucose at 4 ° C. All drugs (norepinephrine, 
acetylcholine, sodium nitroprusside (SNP), L-NNA, 
and papaverine were purchased from Sigma Chemical 
Co. (St. Louis, Mo.). Norepinephfine, acetylcholine, 
and SNP were made fresh daily as stock solutions (10 .3 
mol /L  and 104 tool/L).  The L-NNA and papaverine 
were made each week as stock solutions (10 .2 tool/L)  
and stored at 4 ° C. 
Data calculations and statistical analysis 
Norepinephrine dose-response curves for each 
artery were normalized to the diameter evoked by the 
maximal dose of norepinephfine (10.0 ~tmol/L). 
Relaxation-response curves to acetylcholine and SNP 
were normalized to the level ofprecontraction elicited 
by an intermediate dose of norepinephrine. EC~0 
values for each artery were determined by plotting the 
dose-response curve on a logarithmic scale and ex- 
trapolating from a best-fit line between 20% and 80% 
of the maximal constriction. The ECs0 was deter- 
mined as the value at which the agonist produced 50% 
of the maximal response (i.e., ECs0 ). Maximum 
responses produced by each agonist were calculated as 
a percentage of the relaxed diameter evoked by 
papaverine (0.1 retool/L). The n value on each graph 
represents artery number for each individual proto- 
col. All results are expressed as mean + SE. Differ- 
ences between patient demographics, maximum re- 
sponses, norepinephrine s nsitivity, and relaxations to 
acetylcholine and SNP were determined by one-way 
analysis of variance. For comparisons between arteries 
with and without L-NNA, a paired t test was used. 
Statistical significance was defined as p < 0.05. 
Experimental protocols 
Determination of endothelial involvement in 
arterial reactivity to norepinephrine. Norepineph- 
fine-induced vasoreactivities of vessels with and with- 
out endothelium were compared to determine the 
role of the endothelium in modulating arterial reac- 
tivity to ~-adrenergic stimulation. Two arteries from 
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the same patient--either control subject (n = 13) or 
patient with diabetes (n = 12)--were run simulta- 
neously in the two chambers of the arteriograph; one 
with intact endothelium and one with endothelium 
denuded as described above. After a 60-minute quili- 
bration, the arteries were exposed to increasing con- 
centrations ofnorepinephrine (0.01 to 10.0 gmol /L)  
by cumulatively adding norepinephrine to the arte- 
riograph chamber and recording the diameter at each 
concentration after stable contraction was reached. 
The norepinephrine was then washed out of the bath, 
and the arteries were given an intermediate dose of 
norepinephrine to attain a constriction 30% to 50% of 
the maximum. Once a stable precontraction was 
accomplished, the endothelium-dependent vasodila- 
tot acetylcholine (1.0 gmol /L)  was given to test for 
endothelial integrity, that is, lack of dilation from 
denuded vessels. 
Determinat ion of  nitric oxide involvement in 
arterial reactivity to norepinephrine. To determine 
the vasorelaxant influence of NO in contributing to 
arterial sensitivity to norepinephrine, the arginine 
analog >NNA was used to inhibit synthesis of NO. 
L-NNA is a stereospecific competitive inhibitor of NO 
synthase (NOS), the enzyme responsible for the 
synthesis of NO from >-arginine. 23 Intact arteries 
from control subjects (n -- 9) and patients with dia- 
betes (n = 5) were equilibrated for 60 minutes and 
norepinephrine dose-response curves generated, as 
described above. The norepinephrine was washed 
out, and L-NNA (0.1 mmol /L)  was added to the bath 
and incubated for 20 to 30 minutes. The norepineph- 
rine dose-response curve was then repeated in the 
presence of L-NNA, and the sensitivity to norepi- 
nephrine in the presence and absence of L-NNA was 
compared. 
Stimulated nitric oxide release by acetylcho- 
line. Ace@choline was used to determine whether 
patients with diabetes have altered stimulated release 
of NO. Acetylcholine is an endothelium-dependent 
vasodilator that acts via a receptor-mediated mecha- 
nism (G protein-coupled) to increase production and 
release of NO from the endothelium. 12 Arteries from 
control subjects (n = 8) and patients with diabetes 
(n = 5) were equilibrated and precontracted to 30% 
to 50% of maximum with an intermediate dose 
of norcpinephrine. Ace@choline was cumulatively 
added to the bath (0.003 to 1.0 btmol/L), and the 
diameter recorded after stable relaxation was attained. 
After the last dose of acetylcholine was added (no 
further dilation was produced), papaverine (0.1 
mmol /L)  was added to the bath, and the relaxed 
diameter for each vessel was recorded. 
Determination o f  vascular smooth muscle cell 
responses to sodium nitroprusside. The response of 
arteries to SNP, an endothelium-independent vasodi- 
lator that relaxes mooth muscle via the same cyclic 
guanosine monophosphate-mediated m chanism as 
NO 12, was used to determine the function of the 
smooth muscle within the vascular wall. Intact arteries 
from control subjects (n = 7) and patients with dia- 
betes (n = 5) were equilibrated and precontracted 
with an intermediate dose ofnorepinephrine to attain 
a contraction 30% to 50% of maximum. SNP was 
cumulatively added to the bath, and the diameter at 
each concentration was recorded once a stable diam- 
eter was reached. After the last dose of SNP was added 
(no further dilation was produced), papaverine (0.1 
mmol/L)  was added to the bath, and a fully relaxed 
diameter was recorded. 
RESULTS 
Subjects. All arteries used for experimentation 
were obtained from patients undergoing lower ex- 
tremity arterial surgery. Patient demographics are 
shown in Table I. Experimental groups were age 
matched and had similar body weights. Cholesterol 
levels were within the normal range (160 to 209 
mg/dl)  for all groups; however, many patients were 
receiving cholesterol-lowering medication and were 
considered to have hypercholesterolemia, Triglycer- 
ide levels were not available for most patients. The 
average blood pressure was elevated for both groups, 
averaging 148 + 5 mm Hg in control subjects and 
156 _+ 8 mm Hg in patients with diabetes (men and 
women combined, p > 0.05). The diabetic group, as 
expected, had increased blood glucose levels, which 
was not significantly different between men and 
women. The average serum glucose for patients in the 
nondiabetic ontrol group was 101 + 4 mg/d l  and 
for the patients with diabetes was 277 _+ 30 (men and 
women combined, p < 0.001). 
Endothelial involvement in arterial reactivity 
to norepinephrine. Addition of norepinephrine to
the arteriograph caused a dose-dependent constric- 
tion in both the nondiabetic ontrol and diabetic 
arteries. Diabetic arteries, however, were significantly 
more sensitive to norepinephrine (Fig. 1, A). The 
amount of norepinephrine cessary to contract he 
arteries 50% of maximum (i.e., the ECa0 value) was 
0.35 + 0.05 btmol/L in the control arteries and 
0.16_+ 0.06 gmol /L  in the diabetic arteries 
(p < 0.05). Removal of the endothelium in the non- 
diabetic control vessels caused a twofold increase in 
sensitivity to norepinephrine, decreasing the ECso 
value to 0.14+ 0.03 btmolTL (p < 0.01 vs intact 
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Fig. 1. A, Dose-response curves to norepinephrine ofintact nondiabetic control (closed circles) 
and diabetic (closed triangles) subcutaneous arteries. Diabetic arteries were significantly more 
sensitive to norepinephrine than nondiabetic control arteries (p < 0.05). ECso values are given 
in text. B, Dose-response curves to norepinephrine of intact (closed circles) and denuded (open 
circles) subcutaneous arteries from control subjects without diabetes. Removal of endothelium 
significantly increased sensitivity to norepinephrine (p < 0.05). ECso values are given in text. C, 
Dose-response curves to norepinephrine of intact (closed triangles) and denuded (open triangles) 
subcutaneous arteries from patients with type II diabetes. Denuded arteries had similar sensitivity 
as intact arteries to norepinephrine, and no significant difference was found between ECso values, 
which are given in text. 
control). Endothelial removal in the diabetic vessels 
did not further augment he already elevated sensi- 
tivity to norepinephrine: EC~0 = 0 .17+ 0.05 
txmol/L (p > 0.05 vs intact diabetic). The norepi- 
nephrine dose-response curves for both nondiabetic 
control and diabetic arteries with and without endo- 
thelium is shown in Fig. 1, B and C. 
Nitric oxide involvement in arterial reactivity 
to norepinephrine. In this set of  experiments, the 
diabetic arteries were again more sensitive to norepi- 
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Fig. 2. A, Dose-response curves to norepinephrine of intact subcutaneous arteries in absence 
(closed circles) and presence (open circles) of nitric oxide inhibitor L-NNA (0.1 mmol/L) from 
control subjects without diabetes. Inhibition of NO caused significant increase in sensitivity to 
norepinephrine similar to endothelial removal. ECho values are given in text. B, Dose-response 
curves to norepinephrine of intact subcutaneous arteries in absence (closed triangles) and 
presence (open triangles) of nitric oxide inhibitor L-NNA (0.1 mmol/L) from patients with type 
II diabetes. Inhibition of NO did not affect sensitivity to norepinephrine i  diabetic arteries. ECho 
values are given in text. 
nephrine than the nondiabetic control arteries: con- 
trol EC~0=0.36+0.14  btmol/L vs diabetic 
ECs0 = 0.15 + 0.03 gmol /L  (p < 0.05). After wash- 
ing out the norepinephrine, addition of L-NNA to the 
bath did not significantly alter the resting diameter of 
either the control or the diabetic arteries. Similar to 
endothelial removal, incubation in L-NNA to block 
endothelial NO production increased sensitivity of 
the control vessels to norepinephrine (ECso= 
0.14 _+ 0.04 btmol/L; p < 0.05 vs control without 
L-NNA) but failed to further augment the sensitivity 
of the diabetic vessels (ECso = 0.15 + 0.04 btmol/L; 
p > 0.05 vs diabetic without L-NNA). A graph of the 
norepinephrine dose-response curves with and with- 
out L-NNA for nondiabetic ontrol and diabetic 
arteries is shown in Fig. 2. 
Stimulated nitric oxide release by acetylcho- 
line. Addition of acetylcholine to the bath caused 
a dose-dependent dilation of the arteries from a 
precontracted state. Nondiabetic control vessels 
were significantly less sensitive to the dilator ef- 
fects of acetylcholine than the diabetic vessels: 
ECso(Control ) = 0.040 + 0.010 btmol/L versus 
ECso(diabetic ) = 0.009 +_ 0.001 btmol/L diabetic 
(p < 0.05). A graph of the dose-response curves to 
acctylcholine for both nondiabetic ontrol and dia- 
betic arteries is shown in Fig. 3. 
Sensitivity o f  vascular smooth muscle to SNP. 
Addition of SNP to the arteries caused a dose- 
dependent vasodilation that was similar for both the 
diabetic and nondiabetic control groups: ECs0(con- 
trol) = 0.04+ 0.01 Bmol/L  vs ECso(diabetic ) = 
0.04 ± 0.01 gmol /L  (p > 0.05). A graph of the 
dose=response curves to SNP for both the diabetic 
and nondiabetic control groups are shown in Fig. 4. 
Maximum responses. The constriction induced 
by the highest dose of norepinephrine (10.0 
mmol /L)  was not significantly different between 
nondiabetic control and diabetic arteries, constricting 
73% _-_ 3% and 78% + 4% of the relaxed diameter for 
intact arteries, and 83% _+ 5% and 81% _+ 1%, respec- 
tively, for denuded arteries (p > 0.05 vs intact control 
and diabetic). The maximum relaxations evoked by 
the highest concentration feither acetylcholine (1.0 
btmol/L) or SNP (1.0 btmol/L) were also not differ- 
ent between ondiabetic control and diabetic arteries, 
relaxing 98% -+ 0.1% and 99% +- 0.3% of the diameter 
in papaverine (0.1 mmol /L)  for acetylcholine and 
94% + 2% and 96% _+ 3% for SNP (p > 0.05). 
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Fig. 3. Dose-response curves to acetylcholine of intact 
subcutaneous arteries from control subjects without diabe- 
tes (closed circles) and patients with type II diabetes (closed 
triangles). Diabetic arteries were more sensitive to relax- 
ations evoked by this agonist. ECs0 values are given in text. 
D ISCUSSION 
This study clearly demonstrates that subcutaneous 
resistance arteries from patients with diabetes ex- 
hibit enhanced contractile responses to cz-adrenergic 
stimulation by norepinephrine (Fig. 1, A). The results 
reported herein also establish that in patients without 
diabetes the endothelium attenuates the vasoconstric- 
tion produced by norepinephrine shown by the ob- 
servation that endothelial removal increased the sen- 
sitivity to norepinephrine and decreased the amount 
of  agonist necessary to contract he arteries 50% of 
maximum (ECs0) from 0.35 gmol /L  to 0.14 
gmol /L  (Fig. 1, B). This mitigation was absent in 
diabetic arteries, which showed no augmentation of
sensitivity to norepinephrine on endothelial removal 
(Fig. 1, C); the ECs0 for norepinephrine of both 
intact and denuded iabetic arteries was 0.16 gmol /L  
and 0.17 gmol/L ,  matching that of the denuded 
control arteries. 
The results of this study are consistent with several 
studies that have shown increased reactivity to nor- 
epinephrine in arteries from animals with experimen- 
tally-induced iabetes, -s However, to our kaaowl- 
edge, this is the first study reporting increased nor- 
epinephrine sensitivity in human diabetic resistance 
arteries attributable to abnormal endothelial func- 
tion. The endothelium, through production and 
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Fig. 4. Dose-response curves to sodium nitroprusside of
intact subcutaneous arteries from control subjects without 
diabetes (closed circles) and patients with type II diabetes 
(closed triangles). No significant differences were found 
between ondiabetic control and diabetic arteries. ECs0 
values are given in text. 
release ofvasodilatory substances, is known to be an 
important regulator of vascular eactivity and tone ll 
and has been shown to modulate c~-adrenergic vaso- 
constriction. 24Thus the augmented vasoreactivity to
norepinephrine of diabetic arteries could be due to a 
diminished (or absent) endothelial vasorelaxant in- 
fluence. 
In this study, blockade of NO synthesis by L-NNA 
resulted in enhanced arterial responsiveness to nor- 
epinephrine in the control arteries (Fig. 2, A), similar 
to endothelial removal, suggesting that in these 
arteries the primary endothelial-derived vasorelaxant 
that counteracts norepinephrine-induced vasocon- 
striction is NO. It is unlikely that the increased 
sensitivity to norepinephrine was due to diminished 
basal NO release because blockade of NO synthesis by 
L-NNA did not alter the baseline diameter in either 
control or diabetic arteries. Because vascular endo- 
thelial cells contain (~2-adrenergic receptors, 25nore- 
pinephrine stimulation may activate ndothelial re- 
ceptor-mediated release of NO that could offset the 
agonist-induced vasoconstriction. Removal of the 
endothelium or inhibition of NO synthesis would 
eliminate this vasorelaxant influence and enhance the 
const r ic tor  effect. 24 
Endothelial dysfunction during diabetes has been 
shown to be associated with an impaired NO-medi- 
ated vasodilation. 13-I8 Removal of the endothelium 
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Table I. Patient demographics of the subjects from which biopsies were obtained 
Control Subjects Patients with diabetes 
Men Women Men Women 
n 9 17 7 8 
Age (yrs.) 55 + 6 70 + 4 65 + 4 64 + 5 
Body weight (lbs) 188 _+ 19 172 _+ 15 187 + 22 152 _+ 9 
Glucose (mg/dl)* 90 + 4 106 ± 5 282 _+ 471- 272 _+ 511- 
Hypertension (no./total) 5 /9  (56%) 10/15 (67%) 5/6  (83%) 4 /6  (67%) 
Cholesterol (mg/dl):~ 188 + 15 167 ± 14 177 + 18 209 + 8 
Systolic BP (mm Hg) 145 i 7 150 ± 7 170 ± 13 143 k 5 
*Normal glucose range: 65 to 110 mg/dl.  
I"P < 0.001 vs control subjects. 
:~Normal cholesterol range: 160 to 240 mg/dl.  
from the diabetic arteries did not alter sensitivity to 
norepinephrine, indicating that compared to the 
nondiabetic ontrol arteries, there is a diminished 
vasorelaxant influence by the endothelium. Tesfama- 
riam et al. 26 reported an increased production of 
constrictor prostanoids in rabbit aorta exposed to 
elevated glucose, which they showed to produce 
diminished endothelium-dependent vasorelaxations. 
In the present study, an increased constrictor pros- 
tanoid synthesis in the diabetic arteries is unlikely 
because removal of the endothelium did not cause a 
decrease in sensitivity to norepinephrine, which 
would occur on loss of a vasoconstrictor substance. 
It is important o note that the nondiabetic 
population were all patients of the Vascular Surgery 
service and were therefore at risk for several condi- 
tions that have been shown to cause endothelial 
dysfunction (e.g., hypercholesterolemia, atheroscle- 
rosis, and aging). In our opinion, the lack of a healthy 
control population, however, does not diminish the 
results of this study for several reasons. First, the fact 
that removal of the endothelium and blockade of NO 
caused an increase in norepinephrine s nsitivity in the 
nondiabetic control population, but not in the dia- 
betic group, indicates that the nondiabetic endothe- 
lium is functioning to produce vasorelaxant sub- 
stances, which is a more normal response than the 
diabetic group. Second, the difference in endothelial- 
dependent vasorelaxation between patients with and 
without diabetes with similar vascular disease and risk 
factors only makes it more likely that any difference is
due to diabetes. 
The failure of diabetic arteries to augment sensi- 
tivity to norepinephrine on NO blockade by L-NNA 
(Fig. 2, B) could be due to an attenuated vascular 
smooth muscle (VSM) response to NO-mediated 
dilations; however, relaxations to SNP were unaltered 
in the diabetic arteries (Fig. 4). Because SNP relaxes 
VSM through the same mechanism as endothelium- 
derived NO,  12 a blunted smooth muscle effect is not 
likely. This suggests that type II diabetes causes a 
selective impairment of endothelial NO-mediated 
relaxations without altering the responsiveness of the 
VSM to guanylyl cyclase stimulation. 
Contrary to several reports that have shown di- 
minished acetylcholine-dependent vasodilation i pa- 
tients with diabetes, 1418 this study found arterial 
relaxation to acetylcholine augmented in diabetic 
arteries (Fig. 3). This result is not entirely contradic- 
tory because most previous tudies that demonstrated 
diminished acetylcholine-mediated vasorelaxations i  
human diabetic arteries were performed in arteries 
from patients with type I diabetes (insulin-depen- 
dent). Although studies with patients with type II 
diabetes are limited, there is evidence that type II 
diabetic microvascular bnormalities differ from type 
I. For example, a significant reduction in maximum 
microvascular blood flow was found in the feet of 
patients with newly diagnosed type II diabetes. 2r In 
the present study, the apparent discrepancy between 
endothelial function during adrenergic and muscar- 
inic stimulation may be a manifestation f complica- 
tions noted in the early stages of the disease. McVeigh 
et al., 17 however, reported iminished acetylcholine- 
mediated vasorelaxation i  the forearm of patients 
with type II diabetes but also found a decreased 
sensitivity of the VSM to guanylyl cyclase stimulation 
by glycerol trinitrite, a result not found in this study. 
Synthesis and release of endothelial NO by both 
norepinephrine (0%-adrenergic agonist) and acetyl- 
choline are mediated through G protein-coupled 
receptors on the endothelial cell surface, which act via 
signal transduction pathways to increase intracellular 
calcium. 28 Calcium mobilization is a prerequisite for 
NO production and release. 29 A recent report found 
that patients with type I diabetes have diminished 
relaxation to acetylcholine but not to bradyldnin, 
suggesting that diabetes induces endothelial damage 
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at the receptor level (bradyldnin increases production 
of NO through a similar, but distinct receptor- 
mediated mechanism as acetylcholine28). Therefore 
endothelial dysfunction in diabetic arteries may reside 
at the receptor level (e.g. G protein-coupled recep- 
tors) or in altered signal transduction mechanisms 
(e.g. protein ldnase C) and not in NO production or 
release per se. 
It has been shown that acetylcholine hyperpolar- 
izes the vascular smooth muscle in vitro, causing 
vasorelaxation through mechanisms independent of 
NO. 3° In several studies on isolated blood vessels, 
endothelium-dependent dilations to acetylcholine 
were partially resistant to inhibitors of NO. 11,31 To 
ascertain that the vasorelaxant effects ofacetylcholine 
were due to production and release of NO and not 
some unidentified hyperpolarizing factor, we tested 
the effect of L-NNA on inhibiting acetylcholine- 
mediated vasodilation. The sensitivity to acetylcho- 
line decreased tenfold in the presence of 0.1 mmol/L 
L-NNA (data not shown); however, the vasorelax- 
ations were not completely inhibited. This could be 
due to the concentration of L-NNA used, which may 
be too low to completely inhibit NO production or to 
other vasodilating factors being released by acetylcho- 
line, such as a hyperpolarizing factor. However, 0.1 
mmol/L L-NNA did significantly increase sensitivity 
to norcpinephrine in the nondiabetic ontrol arteries, 
indicating substantial blockade of NO synthesis at this 
dose. In any case, some involvement ofa hyperpolar- 
izing factor in mediating the enhanced sensitivity of 
diabetic arteries to acetylcholine cannot be ruled out. 
It is clear, however, that diabetic subcutaneous resis- 
tance arteries have altered endothelial function, which 
may contribute to enhanced adrenergic reactivity and 
promote the complications of this vascular bed, in-  
cluding chronic ulceration and amputation. 
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